Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 162 Carcinoma, Non-Small-Cell Lung 109 Lung Neoplasms 54 Hodgkin Disease 22 Neoplasm Metastasis 16 Recurrence 15 Lymphoma 15 Neoplasms 14 Triple Negative Breast Neoplasms 13 Prostatic Neoplasms 10 Adenocarcinoma of Lung 10 Sarcoma 9 Rhabdomyosarcoma 9 Uterine Cervical Neoplasms 8 Lymphoma, Non-Hodgkin 8 Lymphoma, Large B-Cell, Diffuse 6 Ovarian Neoplasms 5 Mesothelioma, Malignant 5 Breast Neoplasms, Male 5 Small Cell Lung Carcinoma 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 NSCLC 4 Multiple Myeloma 4 Brain Neoplasms 4 Unspecified Adult Solid Tumor, Protocol Specific 3 Mesothelioma 3 Lymphoma, Mantle-Cell 3 Lymphoma, Large-Cell, Immunoblastic 3 Lymphoma, Follicular 3 Lymphoma, B-Cell, Marginal Zone 3

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rare Tumour × Vinorelbine × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡